Atea Pharmaceuticals, Inc. (AVIR)
- Previous Close
3.6900 - Open
3.7100 - Bid 3.6900 x 300
- Ask 3.7500 x 100
- Day's Range
3.6523 - 3.7200 - 52 Week Range
2.7650 - 5.1900 - Volume
137,512 - Avg. Volume
394,745 - Market Cap (intraday)
312.25M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6300 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
ateapharma.comRecent News: AVIR
Performance Overview: AVIR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVIR
Valuation Measures
Market Cap
310.57M
Enterprise Value
-265.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.89%
Return on Equity (ttm)
-22.74%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-135.96M
Diluted EPS (ttm)
-1.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
578.11M
Total Debt/Equity (mrq)
0.43%
Levered Free Cash Flow (ttm)
-9.44M